Results 71 to 80 of about 14,813,386 (261)

CAR-T cells are serial killers [PDF]

OncoImmunology, 2015
Chimeric antigen receptor (CAR) T cells have enjoyed unprecedented clinical success against haematological malignancies in recent years. However, several aspects of CAR T cell biology remain unknown. We recently compared CAR and T cell receptor (TCR)-based killing in the same effector cell and showed that CAR T cells can not only efficiently kill ...
Alexander J, Davenport, Misty R, Jenkins, David S, Ritchie, H Miles, Prince, Joseph A, Trapani, Michael H, Kershaw, Phillip K, Darcy, Paul J, Neeson   +7 more
openaire   +2 more sources

Differential expression of cancer‐related genes supports prediction of poor response to first‐line treatments in T‐ALL pediatric patients with high minimal residual disease

Molecular Oncology, EarlyView.
In the present work, we have identified a transcriptional signature based on the differential expression of six genes (BCL2&MAST4, HSH2D&LAT2, METRN&PITPNM2) that would facilitate the early detection of T‐cell acute lymphoblastic leukemia (T‐ALL) patients prone to a poor treatment response and could be implemented at diagnosis, along with other risk ...
Antonio Lahera, Laura Vela‐Martín, Pablo Fernández‐Navarro, José Luis López‐Lorenzo, Javier Cornago, Pilar Llamas, Eduardo Pérez‐Gómez, José Luis Marín‐Rubio, Manuel Fresno, Javier Santos, José Fernández‐Piqueras, María Villa‐Morales   +11 more
wiley   +1 more source

CAR-T CELL THERAPY FOR T-CELL MALIGNANCIES

Mediterranean Journal of Hematology and Infectious Diseases
Chimeric antigen receptor T-cell (CAR-T) therapy has revolutionized the treatment of B-cell lymphoid neoplasia and, in some instances, improved disease outcomes.
Ugo Testa, Patrizia Chiusolo, Elvira Pelosi, Germana Castelli, Giuseppe Leone   +4 more
doaj   +1 more source

Recent Advances in the Development of Anti-FLT3 CAR T-Cell Therapies for Treatment of AML

, 2022
Following the success of the anti-CD19 chimeric antigen receptor (CAR) T-cell therapies against B-cell malignancies, the CAR T-cell approach is being developed towards other malignancies like acute myeloid leukemia (AML).
Maya Graham Pedersen, Rasmus O. Bak, Bak, Rasmus O., Møller, Bjarne Kuno, Bjarne Kuno Møller, Pedersen, Maya Graham   +5 more
core   +1 more source

Metastasis on pause: How dormant tumor cells stay hidden within the tumor microenvironment and evade immune surveillance

Molecular Oncology, EarlyView.
Dormant cancer cells can hide in distant organs for years, evading treatment and the immune system. This review highlights how signals from the surrounding tissue and immune environment keep these cells inactive or trigger their reawakening. Understanding these mechanisms may help develop therapies to eliminate or control dormant cells and prevent ...
Kanishka Tiwary, Jose Javier Bravo‐Cordero   +1 more
wiley   +1 more source

Magnesium sensing via LFA-1 regulates CD8+ T cell effector function. [PDF]

, 2022
The relevance of extracellular magnesium in cellular immunity remains largely unknown. Here, we show that the co-stimulatory cell-surface molecule LFA-1 requires magnesium to adopt its active conformation on CD8+ T cells, thereby augmenting calcium flux,
Künzli, Marco, Balmer, Maria L., Schenk, Susanne H., Lotter, Claudia, Grählert, Jasmin, Irving, Melita, Giordano, Greta, Strati, Paolo, Giordano Attianese, Greta Maria Paola, Rothschild, Sacha I., Kuzmin, Dmitry, Litzler, Ludivine, Rothschild, Sacha I, Page, Nicolas, Reith, Walter, King, Carolyn G, Kirchhammer, Nicole, Zippelius, Alfred, Burgener, Anne-Valérie, Cribioli, Elisabetta, Hess, Christoph, Martí I Líndez, Adrià-Arnau, Schenk, Susanne H, Marti Lindez, Adria-Arnau, King, Carolyn G., Schreiner, David, Lee, Dahye, Pless, Miklos, Lenz, Markus, Koch, Victoria, Merkler, Doron, Löliger, Jordan, Trefny, Marcel P., Dehio, Philippe, Huwyler, Jörg, Balmer, Maria L, Lötscher, Jonas, Trefny, Marcel P   +37 more
core   +1 more source

Epigenetic heterogeneity and plasticity in therapy‐induced tumor states through single‐cell multi‐omics

Molecular Oncology, EarlyView.
Single‐cell multi‐omics reveals epigenetic heterogeneity across therapy‐adaptive tumor states, including quiescent/dormant, drug‐tolerant persister, and EMT‐like phenotypes. By linking regulatory features with state‐associated biomarkers, these approaches inform biomarker‐guided therapeutic strategies for evolving tumors.
Hee Jung Kim, Hwiyeong Lee, Jin Hong, Daechan Park   +3 more
wiley   +1 more source

Driving CAR T-cells forward [PDF]

Nature Reviews Clinical Oncology, 2016
The engineered expression of chimeric antigen receptors (CARs) on the surface of T cells enables the redirection of T-cell specificity. Early clinical trials using CAR T cells for the treatment of patients with cancer showed modest results, but the impressive outcomes of several trials of CD19-targeted CAR T cells in the treatment of patients with B ...
Hollie J, Jackson, Sarwish, Rafiq, Renier J, Brentjens   +2 more
openaire   +2 more sources

PAK1 activation drives divergent resistance mechanisms to aromatase inhibition and tamoxifen in a luminal: A breast cancer model

Molecular Oncology, EarlyView.
Breast cancer remains a major cause of cancer death in women, frequently developing endocrine therapy resistance. This study demonstrates that upregulated p21‐activated kinase 1 (PAK1) activity drives resistance to tamoxifen and long‐term estrogen deprivation in ER+ breast cancer models.
Luisa Schwarzmüller, Janina Müller, Efstathios‐Iason Vlachavas, Lukas Beumers, Lena Fleischhacker, Sara Burmester, Angelika Wörner, Sabine Karolus, Dominic Helm, Cindy Körner, Stefan Wiemann   +10 more
wiley   +1 more source

Single‐cell DNA methylation profiling: Technologies, computation, and applications in precision oncology

Molecular Oncology, EarlyView.
Single‐cell DNA methylation (scDNAme) profiling maps epimutational clonal evolution, revealing mechanisms of malignancy and therapeutic resistance across diverse cancer types. By providing a high‐resolution landscape of intratumoral heterogeneity, these technologies empower precise patient stratification, guide the development of enhanced ...
Ik Soo Kim
wiley   +1 more source